{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T20:44:07Z","timestamp":1743453847102},"reference-count":33,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T00:00:00Z","timestamp":1391126400000},"content-version":"unspecified","delay-in-days":30,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Technol Assess Health Care"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Contrast-induced acute kidney injury (CI-AKI) is defined as a deterioration in renal function after administration of radiologic iodinated contrast media (CM). Iodixanol, showed a lower CI-AKI incidence than low-osmolar contrast media (LOCM). A cost-effectiveness analysis was performed comparing iodixanol and LOCM in intravenous (IV) setting in Italy.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>A Markov model was developed. Patients moved across four health states: CI-AKI free, CI-AKI, myocardial infarction, and death. The simulation horizon was lifetime with 1-month cycles. Costs and outcomes were discounted at 3.5 percent rate. CI-AKI incidence was considered from published literature across different definitions. Cost-effectiveness of iodixanol was assessed in terms of incremental cost per life-year gained. Net monetary benefit (NMB) was also calculated. Both deterministic and probabilistic sensitivity analyses were performed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>Base-case results showed an average survival increase of 0.51 life-years and a savings of \u20ac7.25 for iodixanol versus LOCM. The cost-effectiveness of iodixanol was confirmed when other scenarios were explored, such as varying CI-AKI definition, sub-populations with specified risk factors, CM hospital bids prices, and inclusion of adverse drug reactions of allergic nature. An NMB ranging between \u20ac6,007.25 and \u20ac30,007.25 was calculated.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>Base-case results show that IV iodixanol is cost-effective compared with LOCM in the Italian clinical setting of a hospital computed tomography radiology practice. However, some caution is due, mainly linked to inherent limitations of the modeling technique and to the lack of agreement on CI-AKI incidence data in the clinical literature.<\/jats:p>","DOI":"10.1017\/s0266462313000706","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T13:38:32Z","timestamp":1391175512000},"page":"69-77","source":"Crossref","is-referenced-by-count":7,"title":["ECONOMIC EVALUATION OF INTRAVENOUS IODINATED CONTRAST MEDIA IN ITALY"],"prefix":"10.1017","volume":"30","author":[{"given":"Sergio","family":"Iannazzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stijn","family":"Vandekerckhove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"De Francesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Morana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,1,31]]},"reference":[{"key":"S0266462313000706_ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0477-7"},{"key":"S0266462313000706_ref13","doi-asserted-by":"publisher","DOI":"10.3109\/02841851.2010.495350"},{"key":"S0266462313000706_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.01.023"},{"key":"S0266462313000706_ref28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.109.917070"},{"key":"S0266462313000706_ref1","volume-title":"ACR manual on contrast media, version 7","year":"2010"},{"key":"S0266462313000706_ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000332384"},{"key":"S0266462313000706_ref24","first-page":"53","article-title":"Controvalore economico del farmaco e beneficio clinico: Stato dell'arte della metodologia e applicazione di un algoritmo farmacoeconomico","volume":"5","author":"Messori","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"S0266462313000706_ref17","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000016043.87291.33"},{"key":"S0266462313000706_ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.197"},{"key":"S0266462313000706_ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.14"},{"key":"S0266462313000706_ref31","first-page":"3214","article-title":"Elevated relative mortality risk with mild-to-moderate chronic kidney disease decreases with age. Nephrology Dialysis","volume":"22","author":"Raymond","year":"2007","journal-title":"Transplantation"},{"key":"S0266462313000706_ref21","unstructured":"Region Lombardy. Dati relativi alla aggiudicazione della gara regionale per farmaci di contrasto \u2013 Lombardia Informatica e Assessorato regionale alla sanit\u00e0 regione Lombardia, 2011."},{"key":"S0266462313000706_ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021833"},{"key":"S0266462313000706_ref30","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.5.756"},{"key":"S0266462313000706_ref16","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.18.1837"},{"key":"S0266462313000706_ref14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2481071484"},{"key":"S0266462313000706_ref23","unstructured":"SDO. Italian hospital discharge database. 2010. http:\/\/www.salute.gov.it\/ricoveriOspedalieri\/paginaInternaRicoveriOspedalieri.jsp?menu=banca&id=1236&lingua=italiano (Accessed July 2012)."},{"key":"S0266462313000706_ref26","doi-asserted-by":"publisher","DOI":"10.2217\/iim.12.9"},{"key":"S0266462313000706_ref20","unstructured":"Report Multiclient ECMIG 2011 per le Aziende farmaceutiche di settore. GE Healthcare, data on file."},{"key":"S0266462313000706_ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.4315"},{"key":"S0266462313000706_ref27","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2501080833"},{"key":"S0266462313000706_ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000337487"},{"key":"S0266462313000706_ref5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004090740"},{"key":"S0266462313000706_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.07.020"},{"key":"S0266462313000706_ref12","first-page":"145","article-title":"Cost analysis in patients at high risk o f contrast induced nephropathy: Italian results of the NEPHRIC study","volume":"7","author":"Colombo","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"S0266462313000706_ref19","unstructured":"Italian Drug Formulary. ReFI \u2013 Prontuario Farmaceutico Italiano. 2012. http:\/\/www.prontuariofarmaceutico.it\/ (Accessed May 2012)."},{"key":"S0266462313000706_ref32","unstructured":"Framingham Heart Study. Recurring Coronary Heart Disease 2-year risk. 2000. Primary and subsequent coronary risk appraisal: New results from the Framingham Study. Am Heart J. http:\/\/www.framinghamheartstudy.org\/risk\/recurr.html (Accessed July 1, 2012)."},{"key":"S0266462313000706_ref18","unstructured":"ISTAT \u2013 National Institute of Statistics. Tables of mortality of the general population by age and sex. Data 2009. http:\/\/www.demo.istat.it\/index_e.htm (Accessed July 2012)."},{"key":"S0266462313000706_ref33","volume-title":"Il database dell'Italian Network on Congestive Heart Failure (IN-CHF): risultati e prospettive","year":"1999"},{"key":"S0266462313000706_ref25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/oso\/9780192631770.003.0008","volume-title":"Economic evaluation in health care","author":"Briggs","year":"2001"},{"key":"S0266462313000706_ref22","unstructured":"Ministry of Health. DRG, 2006. DECRETO 12 Settembre 2006 Ricognizione e primo aggiornamento delle tariffe massime per la remunerazione delle prestazioni sanitarie. GU n. 289 del 13-12-2006- Suppl. Ordinario n.234. Roma: Ministero della Salute."},{"key":"S0266462313000706_ref7","unstructured":"Canadian Association of Radiologists. Guidelines for the prevention of contrast induced nephropathy. Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett B. Approved: June 17, 2011. www.car.ca. (Accessed July 2012)."},{"key":"S0266462313000706_ref15","first-page":"1393","article-title":"A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention","volume":"44","author":"Mehran","year":"2004","journal-title":"J Am Coll Cardiol"}],"container-title":["International Journal of Technology Assessment in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0266462313000706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T20:41:56Z","timestamp":1716496916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0266462313000706\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0266462313000706"],"URL":"https:\/\/doi.org\/10.1017\/s0266462313000706","relation":{},"ISSN":["0266-4623","1471-6348"],"issn-type":[{"value":"0266-4623","type":"print"},{"value":"1471-6348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}